Secretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional study

Ali Hossein Mesgarzadeh1, Abolfazl Akbarzadeh2*, Ali Rasipour1, Tannaz Rasipour1, Amir Mehdizadeh3 and Maghsod Shaaker4*

Abstract

Background: Oral reactive lesions are the most common lesions of oral cavity. Phospholipases and fatty acids play key roles in the creation of inflammation by change in metabolic activities and production of lipid mediators. The aim of this study was to investigate the amount of secretory phospholipase-A2 (sPLA2) and difference of fatty acid pattern in oral reactive hyperplasia and adjacent normal appearing tissues in patients with oral reactive lesions.

Methods: Paired samples of oral hyperplastic (OH) and adjacent normal-appearing tissue of 45 patients were investigated in this study. The collected samples were analyzed with enzymatic spectrophotometric method in terms of the amount of sPLA2 and composition of fatty acids by gas–liquid chromatography method.

Results: The amount of sPLA2 (1.8-fold, p < 0.001), stearic acid (1.2-fold, p < 0.001), oleic acid (1.1-fold, p = 0.01), arachidonic acid (1.5-fold, p < 0.001) and docosahexaenoic acid (1.3-fold, p = 0.02) were increased, while the amount of palmitoleic acid (−45%, p < 0.001) and linoleic acid (−19%, p < 0.001) were reduced in the OH tissue samples. Furthermore, the results demonstrated significant associations between the type and location of tissue samples with monounsaturated fatty acids (MUFAs) and n−3 polyunsaturated fatty acids. Tissue samples from patients with inflammatory fibroepithelial hyperplasia showed relatively higher MUFAs and lower n−3 polyunsaturated fatty acids than other type of lesions.

Conclusions: Localized changes in the sPLA2 activity and composition of fatty acid are associated with oral reactive hyperplasia and the type of pathological response. We suggest that sPLA2 activity and multiple type of fatty acids might be used as potential therapeutic target for oral reactive hyperplasia.

Keywords: Fatty acids, Hyperplasia, Inflammation, Phospholipase A2, Oral cavity

Background

Oral mucosa is constantly exposed to internal and external stimuli [1]. Inflammatory hyperplasia denotes a wide range of enhanced growths occurring in the oral mucosa. Oral reactive lesions are the most common lesions of oral cavity. Secretory phospholipase A2 (sPLA2) is a family of enzymes that catalyze the hydrolysis of fatty acids in the sn-2 position of glycerophospholipids of plasma membrane [2]. sPLA2 and fatty acids produce a number of key bioactive mediators such as prostaglandins and leukotrienes [3]. Both of them participate actively in the regulation of cellular gene expression by altering and activating the cell surface receptors or activating of transcription factors [3]. Clinical studies have shown that sPLA2 isoforms are increased in various cancers including oral squamous cell carcinoma [4], breast, colon, pancreas, and prostate cancers, and tonsillitis [5–8]. Emerging evidence supports the significance of sPLA2 and fatty acids as biomarkers for inflammation. However,
no study has yet investigated the relationship of oral reactive lesions with sPLA2 and fatty acids so far. Therefore, this study was conducted to investigate the difference in sPLA2 and fatty acids in the oral reactive hyperplasia and adjacent normal appearing tissues, as well as their possible relationship with clinical and pathological characteristics.

**Methods**

**Sampling**

This cross-sectional study was done on a population of patients referred to the department of Oral and Maxillofacial Surgery at Tabriz Faculty of Dentistry to remove reactive lesions of the oral cavity. Exclusion criteria of this study were being over 70 years of age, a history of smoking, alcohol intake, inflammatory or infectious diseases or diabetes.

Paired oral hyperplastic (OH) tissue and adjacent normal-appearing tissue were taken from the same subjects to minimize the possibility of confounding factors. The protocol of this study was reviewed and approved by the ethics committee of Tabriz University of Medical Sciences and informed consent was taken from all patients. Tissue sampling was done consecutively by a single oral and maxillofacial surgeon. Both OH tissue and adjacent normal-appearing tissue (0.5 cm beyond the OH tissue) were obtained at the same time during surgery. We only collected tissue samples from localized reactive lesions in oral cavity. In all cases, presence of a local irritant was the cause of inflammation. The type of adjacent normal-appearing tissue was the same as reactive lesion and was confirmed by postoperative histology. This tissue section was used as the negative control in our study and all measures (sPLA2 and fatty acids) in reactive tissue were compared with that in adjacent normal-appearing tissue.

A total of 45 reactive tissue samples and 45 adjacent normal-appearing tissue were collected from 45 patients. All tissue samples were histologically assessed by a pathologist to confirm histopathologic status, homogeneity and integrity of the tissue. The specimens were divided and either stored at −70 °C for fatty acid analyses or snap-frozen for protein isolation.

**Secretory phospholipase A2 activity**

Total protein was extracted from 20 mg of tissue specimens homogenized in ice-cold lysis buffer containing protease inhibitors, as previously described by us [9]. The suspension was centrifuged and protein concentration in the supernatant was measured using the method of Lowry [10]. The activity of serum sPLA2 was estimated by a standard assay with Diheptanoyl Thio-Phosphatidylcholine as substrate (Cayman Chemicals, Windham, NH, USA) using an Immunoscan model 310 microplate reader (Labsystems, Helsinki, Finland). Values were normalized to the corresponding total protein and expressed as units of sPLA2 activity/mg protein.

**Fatty acid analysis**

Total lipids were extracted from tissue samples and esterified with methanol during catalysis with acetyl chloride [11]. Fatty acid methyl ester mixtures were separated on a 60 × 0.25-mm Teknikroma TR CN100 column using a Buck Scientific model 610 gas chromatograph (SRI Instruments, Torrance, USA) equipped with a split injector and a flame ionization detector. The oven temperature was set at 210 °C, and injector and detector temperature at 265 °C. Fatty acids were identified by comparing the peak retention time and analyzed corresponding standards (Sigma Chemicals, St. Louis, MO, USA), and were quantified by calculation the area under curve.

**Statistical analysis**

Data were tested for normal distribution by histogram and Kolmogorov–Smirnov normality test. Difference in the amount of sPLA2 and fatty acids in the OH and the adjacent normal-appearing tissue was analyzed using paired t test, and an unpaired t test was used for comparing unpaired data. The significant relations between amount of sPLA2 and fatty acids and clinical variables were examined by Pearson correlation test. A p value of <0.05 was considered statistically significant. The power to detect a difference in fatty acids and sPLA2 between tissue sample groups was calculated based on the values of mean, standard deviation and number of samples for paired t test statistical analysis. All analyses were carried out using SPSS for windows version 11.0 (SPSS Inc., Chicago, IL, USA).

**Results**

This study was carried out on 45 patients in which 19 of them were male and 26 of them were female. The reactive tissues included 24 cases with inflammatory fibroepithelial hyperplasia (IFH), 10 cases with irritation fibroma (IF), 6 cases with pyogenic granuloma (PG), and 5 cases with peripheral giant cell lesion (PGCG). Representative histological sections of adjacent normal-appearing tissue and the oral reactive lesions are shown in Fig. 1. Most oral reactive lesions were observed in the anterior mandible (35%). The clinical and pathology details of the study subjects are presented in Table 1.

Table 2 shows the level of sPLA2 quantified by enzymatic spectrophotometric assay and Table 3 presents the level of fatty acids measured by gas–liquid chromatography method in the oral hyperplastic (OH) tissue and adjacent normal-appearing tissue from the same patients with oral reactive lesions.
Significant differences were found between the OH tissue samples and control tissues in sPLA2, palmitoleic acid, stearic acid, oleic acid, linoleic acid, arachidonic acid and docosahexaenoic acid. The amount of sPLA2 (1.8-fold, $p < 0.001$), stearic acid (1.2-fold, $p < 0.001$), oleic acid (1.1-fold, $p = 0.01$), arachidonic acid (1.5-fold, $p < 0.001$) and docosahexaenoic acid (1.3-fold, $p = 0.02$) were increased, while the amount of palmitoleic acid ($-45\%$, $p < 0.001$) and linoleic acid ($-19\%$, $p < 0.001$) were reduced in the OH tissue samples. In the studied patients, body mass index (BMI) was related with linoleic acid ($r = -0.41$, $p < 0.001$) but not in adjacent normal-appearing tissue. Among fatty acid classes, only monounsaturated fatty acids (MUFAs) were significantly different between studied tissues ($p = 0.03$; Fig. 2). The statistical power for detecting the reported differences, when $p < 0.05$, was greater than 75.3%.

No association was found between the activity of sPLA2 and the type or location of the biopsies from patients with oral reactive lesion. However, sPLA2 activity showed strong significant correlations with $n-6$ polyunsaturated fatty acids (PUFAs) in OH tissue ($r = -0.41$, $p < 0.001$) but not in adjacent normal-appearing tissue ($r = -0.03$, $p = 0.81$). The results demonstrated significant associations between the type and location of tissue samples with total MUFA and $n-3$ PUFAs. Tissue samples from patients with IFH lesions showed relatively higher MUFAs and lower $n-3$ PUFAs than other type of lesions (Fig. 3). Posterior mandible showed the lowest amount of MUFA and the highest $n-3$ PUFA as compared to other locations (Fig. 4).

**Discussion**

Given the high prevalence of reactive lesions of the oral cavity and altered metabolism of sPLA2 and fatty acids in the hyperplastic tissues, we investigated the hypothesis that amount of sPLA2 and composition of fatty acids in the reactive tissue and adjacent normal-appearing tissue of oral cavity will be different. The results showed that the amount of sPLA2 and arachidonic acid were increased in hyperplastic tissues. sPLA2 plays a significant role in increasing the fluidity of the cell membrane [12]. As an inflammatory agent, it promotes the inflammation through producing the prostaglandins and leukotrienes [13, 14]. The formation and growth of

**Table 1** Demographic characteristics of the 45 studied patients with oral reactive hyperplasia

| Characteristic                  | Value   |
|---------------------------------|---------|
| Age, years                      | 47.6 ± 14.6 |
| BMI, kg/m²                      | 24.3 ± 3.85 |
| Sex, women %                    | 58      |
| Type of lesion, %               |         |
| IFH                             | 54      |
| IF                              | 22      |
| PG                              | 13      |
| PGCG                            | 11      |
| Location of lesion, %           |         |
| Anterior maxilla                | 27      |
| Posterior maxilla               | 11      |
| Anterior mandible               | 35      |
| Posterior mandible              | 11      |
| Buccal mucosa                   | 16      |

$^a$ Values are mean ± SD

**Table 2** Secretory phospholipase-A2 activity of normal-appearing and oral hyperplastic tissue

| Protein                     | Normal-appearing oral mucosa | Oral hyperplastic lesion | $p$     |
|-----------------------------|------------------------------|--------------------------|---------|
| Secretory phospholipase-A2  | 1.56 ± 0.74                  | 2.88 ± 0.88              | <0.001  |

Values are expressed as mean ± SD. $p$, paired $t$ test. $n = 45$
some tumors has been linked to sPLA2 [4, 15, 16]. Cellular phospholipids is hydrolyzed by sPLA2 and provide precursors for the production of eicosanoids [17, 18]. Eicosanoids are known as mediators of inflammatory and immune responses. Inflammatory reactions are involved in the different stages of cell proliferation [19]. Due to the increased activity of this enzyme in the reactive lesions of oral cavity, it appears that sPLA2 inhibitors can be used to treat these lesions. However, further mechanistic studies in this area are needed.

Fatty acid composition of membrane lipids could modulate several metabolic activities, such as glucose metabolism and permeability of the membrane [20]. In a study conducted by Ciçek et al. [21], it has been shown that amount of arachidonic acid, docosahexaenoic acid, palmitoleic acid, linoleic acid and stearic acid is different in unpaired hyperplastic tissues and normal-appearing marginal tissues [21]. They have collected hyperplastic tissue and control tissue samples from different subjects. However, our samples were paired from the same subject. The difference in our findings with the above mentioned study may be due to difference in sampling methods. Since our samples was paired, it seems that there have been less confounding factors. Arachidonic acid, as an inflammatory precursor, is associated with increased inflammatory cytokines [22] and membrane fluidity [23]. Increased amount of arachidonic acid in the oral reactive lesions of oral cavity in this study was consistent

**Table 3** Fatty acid composition of normal-appearing and oral hyperplastic tissue

| % of total       | Normal-appearing oral mucosa | Oral hyperplastic lesion | p     |
|------------------|------------------------------|--------------------------|-------|
| 14:0 (myristic acid) | 1.54 ± 0.94                  | 1.36 ± 0.99              | 0.09  |
| 16:0 (palmitic acid)     | 43.28 ± 2.14                 | 42.01 ± 3.27             | 0.05  |
| 16:1n−7 trans (trans palmitoleic acid) | 0.26 ± 0.15             | 0.23 ± 0.11              | 0.26  |
| 16:1n−7 (palmitoleic acid)   | 2.98 ± 0.99                 | 1.47 ± 0.82              | <0.001|
| 18:0 (stearic acid)       | 11.37 ± 4.23                | 13.42 ± 3.40             | <0.001|
| 18:1n−9 trans (elaidic acid) | 0.90 ± 0.91             | 0.99 ± 0.66              | 0.55  |
| 18:1n−9 (oleic acid)      | 21.58 ± 4.56                | 23.40 ± 4.44             | 0.01  |
| 18:2n−6 (linoleic acid)   | 13.86 ± 2.92                | 11.27 ± 2.23             | <0.001|
| 20:0 (arachidate)         | 0.17 ± 0.14                 | 0.18 ± 0.11              | 0.72  |
| 18:3n−9 (linolenic acid)  | 0.20 ± 0.12                 | 0.18 ± 0.15              | 0.36  |
| 20:4n−6 (arachidonic acid) | 3.21 ± 1.33               | 4.69 ± 1.70              | <0.001|
| 20:5n−3 (eicosapentaenoic acid) | 0.35 ± 0.24         | 0.40 ± 0.18              | 0.23  |
| 22:6n−3 (docosahexaenoic acid) | 0.30 ± 0.16            | 0.39 ± 0.21              | 0.02  |

Values are expressed as mean ± SD, p, paired t test. n = 45

**Fig. 2** Fatty acids in normal-appearing and oral hyperplastic tissues. Mean ± SD fatty acid content (A saturated; B monounsaturated; C n−6 polyunsaturated; and D n−3 polyunsaturated fatty acids) of normal-appearing and oral hyperplastic tissues (n = 45)
with previous studies and represents a change in the lipid metabolism in hyperplastic tissues.

The results of this study showed altered levels of long chain \( n-3 \) polyunsaturated fatty acids that can be synthesized endogenously from \( \alpha \)-linolenic acid. While other studies have shown anti-inflammatory and anti-neoplastic effects of \( n-3 \) polyunsaturated fatty acids [24–26], its inhibitory effect on cancer cells is under intense investigation [27]. Similar to our data, a recent study has indicated an increase of docosahexaenoic acid in the reactive tissues of oral cavity [21]. Current evidence indicate that inflammatory response influence tissue turnover and availability of docosahexaenoic acid [28]. Notably, nonsurgical periodontal treatment significantly increased the serum levels of \( n-3 \) PUFAs [29]. Furthermore, the relative content of \( n-3 \) PUFAs in membrane phospholipids is higher than in the total cellular lipids. Increased ratio of cellular membrane to tissue volume is a main characteristic of oral hyperplastic and oral cancer tissues. Therefore, it seems that membrane phospholipids are more important in determining the content of DHA in exophytic tissues like oral hyperplasia and oral cancers than in normal margins.

According to the literature, while \( n-3 \) polyunsaturated fatty acids have anti-inflammatory effect, \( n-6 \) polyunsaturated fatty acids have mainly inflammatory effects [30]. In this study, OH tissue had significantly lower \( n-6 \) PUFAs than adjacent control tissue. This decrease may be due to higher consumption of these fatty acids in eicosanoid pathway. This finding could also be indicative of specific changes in different fatty acids.

Studies have shown that saturated fatty acids (SFAs) cause inflammatory response and their high intake is
associated with periodontal disease [31]. In the current study, although total SFA showed no changes, stearic acid was higher in OH tissue compared to control tissue. Metabolic importance of each SFA is different. Indeed, induction of inflammation and apoptosis is not the same among different saturated fatty acids [32, 33].

Fatty acids in each group of SFA, MUFA, n−3 PUFA and n−6 PUFA have properties close to each other. However, it seems that contrary to previous studies where changes in each of these categories of fatty acids is proposed as a diagnosis biomarker, weak or no associations were found in each of these categories of fatty acids with reactive lesions. Instead, each fatty acids showed different and unique association with oral reactive lesions. In a previous study, similar variation trends of sPLA2 and other fatty acids has been reported in oral squamous cell carcinoma [4]. Both malignant and oral reactive lesions are exophytic tissues with inflammatory and hyperplastic presentations. Accordingly, our data show notable similarity between oral cancers and oral reactive tissues in variations of sPLA2 and some fatty acids as major inflammatory factors. Differential diagnosis of oral squamous cell carcinoma and oral hyperplasia is currently based on clinical and pathology examination. It is remained to be investigated in future studies whether there is a difference between oral squamous cell carcinoma and oral hyperplasia in sPLA2 and tissue fatty acids.

Inflammation is heterogeneous in terms of pathogenesis and cellular molecular events. Reactive lesions in oral cavity are characterized by a severe localized inflammation. This inflammation is an immune response that is triggered by localized stimuli, such as mechanical stress and microtrauma, and infections. sPLA2 and cellular fatty acids play a crucial role in inflammatory processes. Inflammatory cytokines can modulate several enzymes related to fatty acid synthesis and degradation. According to our data, BMI of patients was associated with the amount of linoleic acid in control tissue. High BMI is a risk factor for many diseases [34]. Epidemiologic studies show gradual increase in dietary intake of linoleic acid worldwide due to nutritional transitions which has been linked to the development of obesity [35]. As linoleic acid is a precursor of inflammatory mediators, it could be suggested that this n−6 PUFA is a link between BMI and systemic inflammation which is associated with increased risk of inflammatory disorders. In consistent with this hypothesis our results show a significantly lower levels of linoleic acid in OH tissue, possibly due to its local consumption for production of inflammatory mediators.

Our findings showed that the pathologic characteristics and location of oral reactive hyperplasia determine the pattern of fatty acids. MUFA are major plasma fatty acids. Therefore, increased total MUFA in IF and IFH may be due to higher access to blood circulation rather than a result of endogenous metabolic changes. In contrast, the activity of desaturases may negatively be affected in the PG and PGCG lesions. These enzymes endogenously produce MUFA from cellular saturated fatty acids.

A major advantage of this study was direct investigation of paired samples collected from the same patients without any systemic inflammation. However, the number of subjects in the subgroups based on the type of pathological response is relatively small to make definitive conclusions. Moreover, it has been shown that composition of the dietary fatty acids influence tissue fatty acids. Future studies with larger sample size, and more homogenous populations in terms of diet and gender, and analysis of enzymes related to fatty acid synthesis and degradation would be helpful.

Conclusions
It is concluded that localized changes in the sPLA2 activity and composition of fatty acid are associated with oral reactive hyperplasia and the type of pathological response. We suggest that sPLA2 activity and multiple type of fatty acids might be used as potential therapeutic targets for oral reactive hyperplasia.

Abbreviations
sPLA2: secretory phospholipase-A2; SFA: saturated fatty acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; BMI: body mass index; OH: oral hyperplastic; IF: inflammatory fibroepithelial hyperplasia; IF: irritation fibroma; PG: pyogenic granuloma; PGCG: peripheral giant cell lesion.

Authors’ contributions
AR, TR, AM and MS performed experiments and statistical analysis. AHM, AR and AA participated in the design of the study. AHM, AR and AA drafted the manuscript. All authors have read and approved the manuscript. This funding source had no role in the study design, execution, analyses, interpretation of the data. All authors read and approved the final manuscript.

Acknowledgements

Authors would like to appreciate Dr. Masoud Darabi for his technical assistance and for his comments on the revised manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Please contact authors for data request.
Ethics approval and consent to participate
The protocol of this study was reviewed and approved by the ethics committee of Tabriz University of Medical Sciences and informed consent was taken from all patients.

Funding
This paper is based on the DDS thesis of AR and TR, under the supervision of AHM. The research was supported by a grant (research Project Number 1536 and 1439 from the Office of the Vice President for Research at the Tabriz University of Medical Sciences).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 January 2017 Accepted: 30 March 2017 Published online: 27 April 2017

References
1. Effiom OA, Adeyemo WL, Soyele OO. Focal Reactive lesions of the
Niger Med J. 2011;52:35–40.
2. Boyanovsky BB, Webb NR. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther. 2009;23:61–72. http://www.sciencedirect.com/science/article/record/pii/S0920304908003064.
3. Taketomi Y, Ueno N, Kojima T, Sato H, Murase R, Yamamoto K, et al. Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-D1 receptor paracrine axis. Nat Immunol. 2013;14:554–63.
4. Askari M, Darabi M, Zare Mahmudabadi R, Oboodiat M, Fayezi S, Mostakhmin Hosseini Z, et al. Tissue fatty acid composition and secretory phospholipase-A2 activity in oral squamous cell carcinoma. Oncol. Clin Transl. 2014.
5. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 2006;240:9–16.
6. Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J. Elavation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta. 1994;228:91–9.
7. Ezzeddini R, Darabi M, Ghaseami B, Jabbari Y, Abdollahi S, Rashchizadeh et al. Circulating phospholipase-A2 activity in obstructive sleep apnea and recurrent tonsillitis. Int J Pediatr Otorhinolaryngol. 2012;76:471–4.
8. Ezzeddini R, Darabi M, Ghaseami B, Darabi M, Fayezi S, Moghaddam YJ, et al. Tissue fatty acid composition in obstructive sleep apnea and recurrent tonsillitis. Int J Pediatr Otorhinolaryngol. 2013;77:1008–12.
9. Mesgarzadeh AH, Abolfathi AA, Dastgiri S, Shaaker M, Vatankhah AM, Solehakahnamoiee S, et al. Interleukin-1 beta, interleukin-6 and TGF-beta in follicular tissue of impacted third molars. Eur Cytokine Netw. 2011;22:103–6. http://www.sciencedirect.com/science/article/record/pii/S1387313511000044&partnerDIED=40.
10. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the
Folin phenol reagent. J Biol Chem. 1951;193:265–75. http://www.ncbi.nlm.nih.gov/pubmed/14907713. Accessed 16 Jul 2014.
11. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a
one-step reaction. J Lipid Res. 1986;27:114–20.
12. Forlenza CN, Schaeffer EL, Gattaz WF. The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer’s disease. J Neural Transm. 2007;114:231–8.
13. Tong LJ, Dong LW, Liu MS. GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis. Mol Cell Biochem. 1998;189:55–61.
14. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012;33:2899–3009.
15. Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2. J Biol Chem. 2005;280:24968–78.
16. Jiang J, Neubauer BL, Graff JR, Cheddler M, Thomas JE, Roehm NW, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol. 2002;160:667–71.
17. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kaseem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
18. Celenk F, Bayramoglu I, Yilmaz A, Meneweve A, Bayarli Y. Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma. J Craniofac Surg. 2013;24:1114–7.
19. Cummings BS. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol. 2007;74:949–59.
20. Ibarburen M, Lopez DJ, Escrivá PV. The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. Biochem Biophys Acta. 2014;1838:1518–28. doi:10.1016/j.bbamem.2013.12.021.
21. Ciçek Y, Ozmen I, Cankaş V, Dilsiz A, Sahin F. Content and composition of fatty acids in normal and inflamed gingival tissues. Prostaglandins Leukot Essent Fatty Acids. 2005;72:147–51.
22. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. Prog Lipid Res. 2006;45:487–510.
23. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2:355–74.
24. Thommesen L, Sjursen W, Gåsvik K, Hansen W, Brekke OL, Skattebøl E, et al. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear kappa B and expression of ICAM-1. J Immunol. 1998;161:3421–30.
25. Tanaka T, Ogura R, Hidaka T, Sugiyama M. Changes of electron spin resonance membrane fluidity in hexadecane-induced hyperproliferative epidermis. J Invest Dermatol. 1989;93:682–6.
26. Nikolakopoulou Z, Ntellopoulos G, Michael-Titus AT, Parkinson EK. Omega-3 polyunsaturated fatty acids selectively inhibit growth in non- plastic oral keratinocytes by differentially activating ERK1/2. Carcinogenesis. 2013;34:2716–25. doi:10.1093/carcin/bgt257.
27. Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care. 2013;16:156–61.
28. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signallipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31:321–51.
29. Wang S-H, Hung H-C, Tsai C-C, Huang M-C, Wu Y-M, et al. Plasma polyunsaturated fatty acids and periodontal recovery in Taiwanese with periodontitis: a significant relationship. Arch Oral Biol. 2014;59:800–7.
30. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:363–79.
31. Iwasaki M, Manz MC, Moynihan P, Yoshihara A, Muramatsu K, Watanabe R, et al. Relationship between saturated fatty acids and periodontal disease. J Dent Res. 2011;90:861–1.
32. Bunn RC, Cockrell GE, Oo Y, Thrailkill KA, Lumpkin CK Jr, Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovasc Diabetol. 2010;9:73.
33. Hu W, Ross J, Geng T, Cowart LA. Differential regulation of dihydروceramide desaturase by palmitate versus monounsaturated fatty acids: implications for insulin resistance. J Biol Chem. 2011;286:16596–605.
34. Sikars KA. The clinical biochemistry of obesity. Clin Biochem Rev. 2004;25:165–81.
35. Naughton SS, Mathai ML, Hryciw DH, McMaster AJ, Linoleic acid and the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016;125:90–9.